Recent news and posts
MTRC Presents the IVD EU Market Access Attractiveness Index (MAAI) 2027
MTRC, a specialist European MedTech market access consultancy, has developed the IVD EU Market Access Attractiveness Index (MAAI) – Edition 2027, a structured ranking of 12 European markets based on the ease, predictability, and resource requirements associated with establishing reimbursement and payment pathways for in vitro diagnostic (IVD) tests.
The Index evaluates the practical market access conditions faced by manufacturers when introducing standard laboratory-based outpatient IVD tests in Europe. It considers six key factors: market access barriers, predictability, time to market access, evidence requirements, innovative payment schemes, and regional complexity.
The MAAI is designed as a strategic tool for IVD manufacturers planning European launches. It supports market access, HEOR, commercial, leadership, and investment teams in identifying countries with more favorable access conditions, anticipating reimbursement and evidence requirements, and aligning market entry strategies with realistic access timelines. The Index complements broader market prioritization assessments by focusing specifically on the feasibility of establishing viable reimbursement and payment pathways.
In the 2027 edition, Denmark, Norway, and the Netherlands lead the ranking, with MAAI scores of 75, 68, and 63, respectively. Denmark benefits from limited formal access barriers and highly predictable conditions, while Norway combines manageable evidence requirements with fast and predictable processes. The Netherlands offers relatively limited barriers and short timelines, although uncertainty around evidence requirements affects its overall attractiveness.
“European market access for IVD tests is not simply about how quickly reimbursement decisions can be made,” said Oleg Borisenko, Founder and Director of MTRC. “Manufacturers need to understand the barriers they may face, the evidence required, and how predictable the pathway is in practice. The IVD MAAI provides a structured framework to support more informed country prioritization, evidence planning, and market entry decisions.”
Explore the MTRC IVD EU Market Access Attractiveness Index (MAAI) – Edition 2027 to understand how European markets compare in terms of reimbursement barriers, predictability, evidence requirements, and other factors influencing market access.
Join our upcoming webinar on the MAAI 2027
We also invite you to join our upcoming webinar on January 21, 2027, at 17:00 CET, where we will discuss the Index methodology, key findings, and their implications for IVD manufacturers. The session will explore how the rankings can inform market prioritization, reimbursement strategies, evidence-generation planning, and European launch decisions.
To attend, please register using the link.